Ertugliflozin and Metformin Hydrochloride
Brand Names: Segluromet
Methodology & AI Transparency ⓘ
Ertugliflozin and Metformin Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Ertugliflozin and Metformin Hydrochloride is an FDA-registered prescription biguanide (oral-route administration) manufactured/labeled by Merck Sharp & Dohme LLC under National Drug Code 0006-5374, 0006-5370, supplied in 7.5 mg/1 / 1000 mg/1 Tablet, Film Coated and 7.5 mg/1 / 500 mg/1 Tablet, Film Coated for physician-directed therapeutic management.
- 2 Real-world patient consensus: Tracked across 18 patient dosage logs with a 79% satisfaction benchmark (RxCUI RXN-00065374-2324).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($5.7115/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Ertugliflozin and Metformin Hydrochloride tolerability events: nausea (8.4%), headache (8.1%), dizziness (6.7%).
Ask our AI Specialists anything about Ertugliflozin and Metformin Hydrochloride
Ertugliflozin and Metformin Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Ertugliflozin and Metformin Hydrochloride is an FDA-registered prescription biguanide (oral-route administration) manufactured/labeled by Merck Sharp & Dohme LLC under National Drug Code 0006-5374, 0006-5370, supplied in 7.5 mg/1 / 1000 mg/1 Tablet, Film Coated and 7.5 mg/1 / 500 mg/1 Tablet, Film Coated for physician-directed therapeutic management.
Pharmacologically, Ertugliflozin and Metformin Hydrochloride functions within the Biguanide class via oral-route delivery (7.5 mg/1 / 1000 mg/1 Tablet, Film Coated and 7.5 mg/1 / 500 mg/1 Tablet, Film Coated), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 0006-5374, 0006-5370 (manufactured/labeled by Merck Sharp & Dohme LLC).
Systemic exposure to Ertugliflozin and Metformin Hydrochloride reflects Systemic oral bioavailability of roughly 78%–90% following first-pass transit absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (ertugliflozin and metformin hydrochloride), sustaining receptor engagement across a Biphasic clearance with 8–20 hr terminal t½ under Ertugliflozin and Metformin Hydrochloride maintenance half-life window (initial pharmacodynamic onset within 1–4 hrs (peak cmax) for ertugliflozin and metformin hydrochloride response profile).
Dosing protocols (7.5 mg/1 / 1000 mg/1 Tablet, Film Coated or 7.5 mg/1 / 500 mg/1 Tablet, Film Coated or 2.5 mg/1 / 500 mg/1 Tablet, Film Coated or 2.5 mg/1 / 1000 mg/1 Tablet, Film Coated) balance efficacy (79.00% patient satisfaction across 18 logs) against nausea (8.4% of reports), headache (8.1% of reports), dizziness (6.7% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving ertugliflozin and metformin hydrochloride (biguanide); concurrent restricted medications flagged in section 4/7 of the ertugliflozin and metformin hydrochloride dailymed monograph (rxn-00065374-2324).
Assess baseline hepatic panels and interacting prescriptions when starting Ertugliflozin and Metformin Hydrochloride (biguanide).
Botanical enzyme modulators may alter oral first-pass exposure of Ertugliflozin and Metformin Hydrochloride; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Ertugliflozin and Metformin Hydrochloride (biguanide)
- Concurrent restricted medications flagged in Section 4/7 of the Ertugliflozin and Metformin Hydrochloride DailyMed monograph (RXN-00065374-2324)
Logged Side-Effect Incidence (18 Reports)
Ertugliflozin and Metformin Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ertugliflozin and Metformin Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Heart failure outcomes captured by adverse event reporting in participants with: What a 8,238-Participant Study Found The effect of ertugliflozin was consistent across the spectrum of total investigator-reported HF AEs and was similar in magnitude to adjudicated HHF events. European journal of heart failure • 2025-03-15 • Phase III Randomized Trial | N = 8,238 | 96/100 | PMID 39792342 ↗ |
| New Insights on Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A: What a 402-Participant Study Found Trial registration Identifier EudraCT Nr. American heart journal • 2022-04-15 • Phase III Randomized Trial | N = 402 | 93/100 | PMID 35045327 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term real-world benefits and safety of ertugliflozin in patients with type 2 Ertugliflozin maintained improvements from baseline in HbA1c, FPG, body weight and SBP through week 104. Diabetes, obesity & metabolism • 2019-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 30614616 ↗ |
Ertugliflozin and Metformin Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $5.7115/unit (~$171.34/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Ertugliflozin and Metformin Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ertugliflozin and Metformin Hydrochloride RxNorm Concept ID | RXN-00065374-2324 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $5.7115 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 79.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ertugliflozin and Metformin Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Ertugliflozin and Metformin Hydrochloride integrating DailyMed SPL (2026-07-01), CMS NADAC ($5.7115/unit), and 18 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ertugliflozin and Metformin Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.